Spruce Biosciences Inc Ordinary Shares SPRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Spruce Biosciences Joins the Russell 3000® Index
-
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
-
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
-
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
-
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
-
Spruce Biosciences to Participate in Upcoming Conferences in June
-
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
-
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
Trading Information
- Previous Close Price
- $45.44
- Day Range
- $44.26–46.45
- 52-Week Range
- $7.75–240.00
- Bid/Ask
- $44.21 / $45.38
- Shares Outstanding
- 2.75M
- Market Cap
- $121.90M
- Volume/Avg
- 34,473 / 75,816
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
Valuation
|
Metric
|
SPRB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SPRB
|
|---|---|
Quick Ratio | 4.59 |
Current Ratio | 4.67 |
Interest Coverage | −51.65 |
Quick Ratio
SPRB
Profitability
|
Metric
|
SPRB
|
|---|---|
Return on Assets (Normalized) | −86.32% |
Return on Equity (Normalized) | −138.32% |
Return on Invested Capital (Normalized) | −125.15% |
Return on Assets
SPRB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%?QZ@&Y | LOCK|gB?%v | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@D#@pl | LOCK|?>!& | $70B | |||
| argenx SE ADR
ARGX
| LOCK|!%Mnj> | LOCK|s^ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>#>XL<# | LOCK|J%s? | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#XYkyh | LOCK|MV@ | $37B | |||
| Moderna Inc
MRNA
| LOCK|$f?&qJ | LOCK|rkF | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kqFj&zV | LOCK|lStnv | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|!MpPm^ | LOCK|&Q | $23B | |||
| Incyte Corp
INCY
| LOCK|j?KK!&$ | LOCK|MpV | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Bz?g$> | LOCK|R? | $16B |
United States